

Table 1. Baseline demographics of patients undergoing evaluation to index drug

	Total number of evaluations (n=331) No. (%)	Negative drug evaluation (false drug allergy label) (n=248) No. (%)	Positive drug evaluation (true drug allergy label) (n=83) No. (%)	<i>P</i> value
Age, mean (SD), years	49 (17)	49 (17)	49 (15)	0.87
Sex, male	123 (37)	102 (41)	21 (25)	0.01
Sex, female	208 (63)	146 (59)	62 (75)	
Comorbidities				
Angioedema-urticaria	16 (5)	12 (5)	4 (5)	0.99
Atopic dermatitis	16 (5)	10 (4)	6 (7)	0.24
Cardiac ^a	128 (39)	89 (36)	39 (47)	0.07
Respiratory ^b	42 (13)	33 (13)	9 (11)	0.56
No. of pre-existing drug allergies				0.70
0–2	159 (48)	119 (48)	40 (48)	
3–4	87 (26)	68 (27)	19 (23)	
≥5	85 (26)	61 (25)	24 (29)	
Class of drug evaluated				<0.01
Beta-lactam antibiotics	170 (51)	114 (46)	56 (68)	
Peri-operative drugs	53 (16)	48 (19)	5 (6)	
NSAIDs	38 (12)	25 (10)	13 (16)	
Non-beta-lactam antibiotics ^c	27 (8)	24 (10)	3 (4)	
Others ^d	43 (13)	37 (15)	6 (7)	
Time from reaction to evaluation				0.85
<6 months	40 (12)	32 (13)	8 (10)	
6–12 months	49 (15)	35 (14)	14 (17)	
1–5 years	76 (23)	53 (21)	23 (28)	
5–10 years	25 (8)	20 (8)	5 (6)	
>10 years	102 (31)	80 (32)	22 (27)	
Unknown	39 (12)	28 (11)	11 (13)	
Latency				0.19
<4 hours	125 (38)	89 (36)	35 (43)	
>4 hours	94 (28)	71 (29)	23 (28)	
Unknown	112 (34)	88 (35)	24 (29)	
Type of index reaction				
Rash not otherwise specified	133 (40)	99 (40)	34 (41)	0.87
Angioedema	85 (26)	58 (23)	27 (33)	0.10
Urticaria	57 (17)	42 (17)	15 (18)	0.81
Itch	48 (15)	35 (14)	13 (16)	0.73

Anaphylaxis	28 (9)	22 (9)	6 (7)	0.64
Unknown	30 (9)	21 (9)	9 (11)	0.51
Respiratory ^e	27 (8)	21 (9)	6 (7)	0.72
Isolated hypotension	13 (4)	9 (4)	4 (5)	0.63
Others ^f	33 (10)	26 (11)	7 (8)	0.59
Pre-evaluation risk stratification				<0.01
Low	57 (17)	50 (20)	7 (8)	
Moderate	222 (67)	172 (69)	50 (60)	
High	52 (16)	26 (11)	26 (31)	

NSAIDs: non-steroidal anti-inflammatory drugs; SD: standard deviation

^a Cardiac comorbidities including hypertension, hyperlipidaemia, ischaemic heart disease.

^b Respiratory comorbidities including asthma, allergic rhinitis.

^c Non-beta-lactam antibiotics: macrolides = 9, fluoroquinolones = 9, metronidazole = 7, vancomycin = 1, tetracycline = 1.

^d Other drugs evaluated: proton pump inhibitors = 8; opioids = 7; anti-emetics = 5; corticosteroids = 3; anti-hypertensives, anti-platelet, mecobalamin/cyanobalamin, statins, antihistamines = 2 each; anti-tussives, allopurinol, somatotropin, anti-spasmodic, insulin, mesalazine, colchicine, levodopa-benserazide, diuretic, erythropoietin = 1 each.

^e Respiratory reactions including breathlessness, wheezing, globus sensation, chest tightness.

^f Other index reactions: gastrointestinal = 9; fixed drug eruption or blisters = 3; erythema or flushing, rhinorrhoea/lacrimation/chemosis, syncope = 3 each; myoclonic jerks, giddiness, palpitations, fever/chills = 2 each; lethargy, diaphoresis, paraesthesia, pain, family history of allergy = 1 each.